임상 한눈에 보기

• 11건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 11건 · 완료/종료 0건
• Phase: Phase 2 · Phase 3 · Phase 1, Phase 2 · Phase 1
• Status: Recruiting · Active, not recruiting
• 주요 endpoint: Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry. · Establishing predictive and prognostic indices based on qualification and exploratory markers to predict pCR and residual cancer burden (RCB). · To determine three- and five-year relapse-free survival (RFS) and OS among the treatment arms. · To determine incidence of adverse events (AEs) · serious adverse events (SAEs)
• 등록 대상자(표본 합산): 약 11,516명
• 선택한 코호트 보고값: ORR 56.5%
• 핵심: This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies w…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.